Compare PNI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNI | TENX |
|---|---|---|
| Founded | 2002 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 71.1M |
| IPO Year | N/A | 2001 |
| Metric | PNI | TENX |
|---|---|---|
| Price | $6.83 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 46.5K | ★ 8.5M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.54 | $1.31 |
| 52 Week High | $7.20 | $19.40 |
| Indicator | PNI | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 37.16 | 18.90 |
| Support Level | $6.64 | $1.31 |
| Resistance Level | $7.07 | $16.39 |
| Average True Range (ATR) | 0.05 | 0.35 |
| MACD | -0.00 | -0.41 |
| Stochastic Oscillator | 11.11 | 3.04 |
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.